Updated on 3 February 2014
"This is very positive reinforcement of what we have come to expect for BNC105," said Dr. Deborah Rathjen, CEO and MD, Bionomics.
The market for drugs to treat ovarian cancer is valued at over $2 billion per annum and there remains significant unmet need for effective treatments. The trials are being conducted across six sites by the Australian and New Zealand Gynaecological Oncology Group (ANZGOG), the National Health and Medical Research Council Clinical Trials Centre (NH&MRC CTC) and the Hoosier Oncology Group in the US.
"Some adverse effects were witnessed in patients but these were of haematological origin consistent with the backbone of the carboplatin and gemcitabine drug combination," said Dr José Iglesias, chief medical Officer, Bionomics.
Principal investigator for the trial, Dr Danny Rischin, commented that, "The results support continued development of BNC105 in the ovarian cancer setting to further investigate the potential of BNC105 as a new drug that may have a clinically significant impact."